Quoin Pharmaceuticals Ltd. has announced a significant step in its growth strategy by filing a prospectus supplement for the sale of up to $11 million in American Depositary Shares (ADSs). This move is crucial for the company as it seeks to enhance its capital resources to support ongoing clinical trials and development of its lead product, QRX003, aimed at treating rare diseases.

Quoin Pharmaceuticals, listed on the Nasdaq under the ticker QNRX, is a late-stage clinical specialty pharmaceutical company focused on developing and commercializing therapeutic products for rare and orphan diseases. The company operates under the Standard Industrial Classification (SIC) of 2834, which covers pharmaceutical preparations. Its recent filings include a series of forms, with the latest being a 424B5 filed on November 4, 2026, under accession number 0001104659-26-122776.

Background

Founded in 1986 and incorporated in Israel, Quoin Pharmaceuticals has undergone several name changes and strategic shifts over the years. The company is now dedicated to addressing the unmet medical needs of patients suffering from rare genetic disorders. Its lead product, QRX003, is currently in pivotal clinical testing for Netherton Syndrome, a rare hereditary condition. Quoin has established clinical sites in the U.S. and U.K. and is also exploring international partnerships to broaden its reach.

What the Filing Says

The recent filing indicates that Quoin has entered into a Sales Agreement with Leerink Partners LLC, allowing the company to sell ADSs representing its ordinary shares. The company may offer and sell these ADSs having an aggregate offering price of up to $11 million. The sales will be conducted as an “at-the-market offering,” meaning shares may be sold at prevailing market prices.

“We have entered into a Sales Agreement... relating to the sale of American Depositary Shares,” the filing states.

Leerink Partners will act as the sales agent and is entitled to a commission of 3% on the gross proceeds from any sales made under this agreement. The filing also notes that as of the date of the prospectus, the aggregate market value of Quoin's outstanding ordinary shares held by non-affiliates was approximately $33 million.

Impact

This capital raise could significantly impact Quoin Pharmaceuticals' ability to fund its clinical trials and development efforts. Investors and stakeholders in the pharmaceutical industry will be closely observing how this financing affects Quoin's progress with QRX003 and its other product candidates. The move may also influence competitors in the pharmaceutical preparations sector, as they assess their own funding strategies in a challenging market.

What's Next

The filing does not specify what happens next, but it is expected that Quoin will proceed with the sales of ADSs as outlined in the agreement with Leerink Partners. This funding will be critical as the company advances its clinical programs and seeks to bring its innovative treatments to market.